Skip to main content
Premium Trial:

Request an Annual Quote

Gradalis Raises $24M in Series B

Premium

Gradalis announced this week that it has closed a $24 million Series B round of financing.

The money, the firm said, would be used to fund late-stage clinical development of its FANG cancer vaccine, and to ramp up manufacturing to accommodate the therapy's commercial launch. The funding will also be used to advance Gradalis' bi-functional shRNA drug candidates.

The FANG vaccine, which incorporates the shRNA technology, is currently in phase II testing in patients with ovarian cancer, advanced melanoma, and colorectal cancer. Gradalis also has a purely RNAi cancer drug in phase I.

A company official recently told Gene Silencing News that the firm is aiming to expand the use of its technology through partnerships (GSN 10/11/2012).

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.